These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30585592)

  • 1. [A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms].
    Kovrigina AM
    Arkh Patol; 2018; 80(6):43-49. PubMed ID: 30585592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
    Vardiman JW
    Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
    Găman M; Vlădăreanu AM; Radesi S
    Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
    Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellström-Lindberg E; Tefferi A; Bloomfield CD
    Blood; 2009 Jul; 114(5):937-51. PubMed ID: 19357394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
    Vardiman J; Hyjek E
    Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?
    Sangiorgio VFI; Orazi A; Arber DA
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101139. PubMed ID: 32460987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current diagnosis of myeloproliferative neoplasms (2008 WHO classification)].
    Frenkel' MA
    Klin Lab Diagn; 2011 Jan; (1):43-9. PubMed ID: 21433318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
    Yin CC; Medeiros LJ; Bueso-Ramos CE
    Int J Lab Hematol; 2010 Oct; 32(5):461-76. PubMed ID: 20626469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms.
    Loghavi S; Kanagal-Shamanna R; Khoury JD; Medeiros LJ; Naresh KN; Nejati R; Patnaik MM;
    Mod Pathol; 2024 Feb; 37(2):100397. PubMed ID: 38043791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic and myeloproliferative disorders in children.
    Hasle H
    Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythroid proliferations in myeloid neoplasms.
    Wang SA; Hasserjian RP
    Hum Pathol; 2012 Feb; 43(2):153-64. PubMed ID: 22154053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.
    Nann D; Fend F
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases.
    Vardiman JW
    Semin Diagn Pathol; 2003 Aug; 20(3):154-79. PubMed ID: 14552429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic Syndrome Updated.
    Hasserjian RP
    Pathobiology; 2019; 86(1):7-13. PubMed ID: 30041243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.